---
document_datetime: 2026-01-26 10:45:12
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tevimbra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tevimbra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0276943
conversion_datetime: 2026-01-29 11:58:10.189855
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tevimbra

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                    |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------|
| Variation type II /  | This was an application for a group of | 18/09/2025                          | 24/10/2025                                  | SmPC and PL                      | The recommended dose of Tevimbra is either |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000269879   | variations.   | 200mg once every 3weeks or 400mg once every 6weeks administered by intravenous infusion.   |
|---------------------|---------------|--------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| PSUR / EMA/PSUR/0000257798               | In view of available data on the safety of tislelizumab in patients with pre-existing autoimmune disease, from the literature, and in view of a plausible mechanism of action, the PRAC Rapporteur considers a causal relationship between tislelizumab and an increased risk of immune-related AEs in patients with pre-existing autoimmune disease is at least a reasonable possibility. The PRAC Rapporteur concluded that the product information of products containing tislelizumab should be amended accordingly.   | 24/07/2025   | 17/09/2025   | SmPC and PL     | Variation   |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|-------------|
| Variation type IA_IN / EMA/VR/0000285978 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is responsible include batch release - Accepted                                                                                                                                                                                                                                                             | 14/07/2025   | 17/09/2025   | Annex II and PL |             |
| Variation type IB / EMA/VR/0000272164    | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.2 Change in test procedure for active substance or starting                                                                                                                                                   | 03/06/2025   | N/A          |                 |             |

<div style=\"page-break-after: always\"></div>

|                                       | material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.II.h.1.b Replacement of obsolete studies related to manufacturing steps and adventitious agents already reported in the dossier - B.II.h.1.b.2 without modification of risk assessment - Accepted   |            |            |             |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| Variation type IB / EMA/VR/0000269138 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.3 After dilution or reconstitution (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                 | 02/06/2025 | 17/09/2025 | SmPC and PL |
| Variation type IB / EMA/VR/0000266115 | This was an application for a group of variations. B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part                                                         | 28/05/2025 | N/A        |             |

<div style=\"page-break-after: always\"></div>

|                                          | of the approved dossier - B.I.d.1.z Other variation - Accepted                                                                                                                 |            |     |                        |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| Variation type IA_IN / EMA/VR/0000271889 | A. ADMINISTRATIVE CHANGES - A.1 Change in the name and/or address of the marketing authorisation holder - Accepted                                                             | 13/05/2025 |     | SmPC, Labelling and PL |
| Variation type IA_IN / EMA/VR/0000255439 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted | 19/03/2025 | N/A |                        |